Biogen (BIIB) Research & Development (2009 - 2026)
Biogen (BIIB) posted quarterly Research & Development of $529.6 million for Q2 2026, up 32.73% year-over-year from $399.0 million in Q2 2025, and down 1.74% quarter-over-quarter from $539.0 million in Q1 2026.
Biogen (BIIB) Research & Development (2009 - 2026) Analysis & Trends
Biogen's Research & Development history runs 18 years deep, the most recent figure standing at $529.6 million for Q2 2026.
- In Q2 2026, Research & Development rose 32.73% year-over-year to $529.6 million; the TTM figure through Jun 2026 stood at $2.0 billion (up 8.13% YoY), while the FY2025 annual figure was $1.8 billion, down 10.19% from the prior year.
- Research & Development for Q2 2026 stood at $529.6 million, down from $539.0 million in the prior quarter.
- The five-year high for Research & Development was $736.3 million in Q3 2023, with the low at $75.0 million in Q4 2023.
- The 5-year median for Research & Development is $522.4 million (2024), against an average of $501.4 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 87.53% in 2023, then soared 584.4% in 2024.
- Biogen's Research & Development stood at $601.6 million in 2022, then sank by 87.53% to $75.0 million in 2023, then jumped by 584.4% to $513.3 million in 2024, then dropped by 0.76% to $509.4 million in 2025, then climbed by 3.97% to $529.6 million in 2026.
- Business Quant data shows BIIB's Research & Development at $529.6 million in Q2 2026, $539.0 million in Q1 2026, and $509.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 529.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 529.60 Mn |
| Mar 31, 2026 | 539.00 Mn |
| Dec 31, 2025 | 509.40 Mn |
| Sep 30, 2025 | 436.10 Mn |
| Jun 30, 2025 | 399.00 Mn |
| Mar 31, 2025 | 434.10 Mn |
| Dec 31, 2024 | 513.30 Mn |
| Sep 30, 2024 | 516.20 Mn |
| Jun 30, 2024 | 505.40 Mn |
| Mar 31, 2024 | 445.40 Mn |
| Dec 31, 2023 | 75.00 Mn |
| Sep 30, 2023 | 736.30 Mn |
| Jun 30, 2023 | 584.20 Mn |
| Mar 31, 2023 | 570.60 Mn |
| Dec 31, 2022 | 601.60 Mn |
| Sep 30, 2022 | 549.20 Mn |
| Jun 30, 2022 | 528.60 Mn |
| Mar 31, 2022 | 551.70 Mn |
| Dec 31, 2021 | 699.50 Mn |
| Sep 30, 2021 | 702.40 Mn |